-
Media Release
Novartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
-
Media Release
Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
-
Media Release
Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
-
Media Release
Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
-
Media Release
Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
-
Media Release
Novartis Hosts Competition to Create Novel Mobile Solutions for Heart Failure Caregivers
-
Media Release
Novartis Hosts Competition to Create Novel Mobile Solutions for Heart Failure Caregivers
-
Media Release
Novartis announces new data on the effects of investigational RLX030 on kidney blood flow in chronic heart failure patients
-
Media Release
Novartis announces new data on the effects of investigational RLX030 on kidney blood flow in chronic heart failure patients
-
Media Release
Novartis Exelon® Patch now FDA approved to treat patients across all stages of Alzheimer's disease
-
Media Release
Novartis Exelon® Patch now FDA approved to treat patients across all stages of Alzheimer's disease
-
Media Release
TV Host Phil Keoghan and Novartis team up to inspire people with MS through innovative tandem cycling campaign